Peripheral Blood Cells from Children with RASopathies Show Enhanced Spontaneous Colonies Growth in Vitro and Hyperactive RAS Signaling

Overview

Journal Blood Cancer J

Date 2015 Jul 18

PMID 26186557

Citations 3

Authors

G Gaipa

C Bugarin

P Cianci

J Sarno

P Bonaccorso

A Biondi

A Selicorni

Affiliations

Soon will be listed here.

Abstract

Germline mutations in genes coding for molecules involved in the RAS/RAF/MEK/ERK pathway are the hallmarks of a newly classified family of autosomal dominant syndromes termed RASopathies. Myeloproliferative disorders (MPDs), in particular, juvenile myelomonocytic leukemia, can lead to potentially severe complications in children with Noonan syndrome (NS). We studied 27 children with NS or other RASopathies and 35 age-matched children as control subjects. Peripheral blood (PB) cells from these patients were studied for in vitro colony-forming units (CFUs) activity, as well as for intracellular phosphosignaling. Higher spontaneous growth of both burst-forming units-erythroid (BFU-E) and CFU-granulocyte/macrophage (CFU-GM) colonies from RAS-mutated patients were observed as compared with control subjects. We also observed a significantly higher amount of GM-colony-stimulating factor-induced p-ERK in children with RASopathies. Our findings demonstrate for the first time that PB cells isolated from children suffering from NS or other RASopathies without MPD display enhanced BFU-E and CFU-GM colony formation in vitro. The biological significance of these findings clearly awaits further studies. Collectively, our data provide a basis for further investigating of only partially characterized hematological alterations present in children suffering from RASopathies, and may provide new markers for progression toward malignant MPD in these patients.

Citing Articles

Combined HRAS and NRAS ablation induces a RASopathy phenotype in mice.

Fuentes-Mateos R, Garcia-Navas R, Fernandez-Infante C, Hernandez-Cano L, Calzada-Nieto N, Olarte-San Juan A Cell Commun Signal. 2024; 22(1):332.

PMID: 38886790 PMC: 11184836. DOI: 10.1186/s12964-024-01717-4.

CanCHD Study of Hematopoietic Cancers in Children With and Without Genetic Syndromes.

Hasan M, Ganni E, Liu A, Guo L, Mackie A, Kaufman J J Am Heart Assoc. 2023; 13(1):e026604.

PMID: 38156460 PMC: 10863797. DOI: 10.1161/JAHA.122.026604.

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.

Khoury J, Solary E, Abla O, Akkari Y, Alaggio R, Apperley J Leukemia. 2022; 36(7):1703-1719.

PMID: 35732831 PMC: 9252913. DOI: 10.1038/s41375-022-01613-1.

References

Liu X, Qu C . Protein Tyrosine Phosphatase SHP-2 (PTPN11) in Hematopoiesis and Leukemogenesis. J Signal Transduct. 2011; 2011:195239. PMC: 3135119. DOI: 10.1155/2011/195239. View

Chan G, Kalaitzidis D, Usenko T, Kutok J, Yang W, Mohi M . Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis. Blood. 2009; 113(18):4414-24. PMC: 2676094. DOI: 10.1182/blood-2008-10-182626. View

Niemeyer C . RAS diseases in children. Haematologica. 2014; 99(11):1653-62. PMC: 4222471. DOI: 10.3324/haematol.2014.114595. View

De Rocca Serra-Nedelec A, Edouard T, Treguer K, Tajan M, Araki T, Dance M . Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature. Proc Natl Acad Sci U S A. 2012; 109(11):4257-62. PMC: 3306697. DOI: 10.1073/pnas.1119803109. View

Choong K, Freedman M, Chitayat D, Kelly E, Taylor G, Zipursky A . Juvenile myelomonocytic leukemia and Noonan syndrome. J Pediatr Hematol Oncol. 1999; 21(6):523-7. View

Kratz C, Niemeyer C, Castleberry R, Cetin M, Bergstrasser E, Emanuel P . The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease. Blood. 2005; 106(6):2183-5. PMC: 1895140. DOI: 10.1182/blood-2005-02-0531. View

Tartaglia M, Niemeyer C, Fragale A, Song X, Buechner J, Jung A . Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet. 2003; 34(2):148-50. DOI: 10.1038/ng1156. View

Bastida P, Garcia-Minaur S, Ezquieta B, Dapena J, Sanchez de Toledo J . Myeloproliferative disorder in Noonan syndrome. J Pediatr Hematol Oncol. 2010; 33(1):e43-5. DOI: 10.1097/MPH.0b013e3181e7571e. View

Schubbert S, Shannon K, Bollag G . Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 2007; 7(4):295-308. DOI: 10.1038/nrc2109. View

10.

Xu D, Wang S, Yu W, Chan G, Araki T, Bunting K . A germline gain-of-function mutation in Ptpn11 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hematopoietic stem cells. Blood. 2010; 116(18):3611-21. PMC: 2981480. DOI: 10.1182/blood-2010-01-265652. View

11.

Emanuel P, Bates L, Castleberry R, Gualtieri R, Zuckerman K . Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood. 1991; 77(5):925-9. View

12.

Kotecha N, Flores N, Irish J, Simonds E, Sakai D, Archambeault S . Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. Cancer Cell. 2008; 14(4):335-43. PMC: 2647559. DOI: 10.1016/j.ccr.2008.08.014. View

13.

Strullu M, Caye A, Lachenaud J, Cassinat B, Gazal S, Fenneteau O . Juvenile myelomonocytic leukaemia and Noonan syndrome. J Med Genet. 2014; 51(10):689-97. DOI: 10.1136/jmedgenet-2014-102611. View

14.

Schiro R, Longoni D, Rossi V, Maglia O, Doni A, Arsura M . Suppression of juvenile chronic myelogenous leukemia colony growth by interleukin-1 receptor antagonist. Blood. 1994; 83(2):460-5. View

15.

Hasegawa D, Bugarin C, Giordan M, Bresolin S, Longoni D, Micalizzi C . Validation of flow cytometric phospho-STAT5 as a diagnostic tool for juvenile myelomonocytic leukemia. Blood Cancer J. 2013; 3:e160. PMC: 3880439. DOI: 10.1038/bcj.2013.56. View

16.

Mohi M, Williams I, Dearolf C, Chan G, Kutok J, Cohen S . Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell. 2005; 7(2):179-91. DOI: 10.1016/j.ccr.2005.01.010. View

17.

Hasle H . Malignant diseases in Noonan syndrome and related disorders. Horm Res. 2009; 72 Suppl 2:8-14. DOI: 10.1159/000243773. View

18.

Tartaglia M, Mehler E, Goldberg R, Zampino G, Brunner H, Kremer H . Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet. 2001; 29(4):465-8. DOI: 10.1038/ng772. View

19.

Bader-Meunier B, Tchernia G, Mielot F, Fontaine J, Thomas C, Lyonnet S . Occurrence of myeloproliferative disorder in patients with Noonan syndrome. J Pediatr. 1997; 130(6):885-9. DOI: 10.1016/s0022-3476(97)70273-7. View

20.

Tartaglia M, Martinelli S, Stella L, Bocchinfuso G, Flex E, Cordeddu V . Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. Am J Hum Genet. 2005; 78(2):279-90. PMC: 1380235. DOI: 10.1086/499925. View